J Rheum Dis.  2022 Jul;29(3):187-189. 10.4078/jrd.2022.29.3.187.

A Case of Superficial Thrombo-occlusive Vascular Disease in a Patient With Rheumatoid Arthritis

• Park Sj
• Joung Ci
• Cheong SH
• Ryu HY
• Lee GH
• Pyo GJ
• Kwon M

• KMID: 2530683
• DOI: http://doi.org/10.4078/jrd.2022.29.3.187

Reference

1. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. 2016; Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol. 3:e72–9. DOI: 10.1016/S2352-3026(15)00251-3.

2. Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, et al. 2017; Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 4:e105–13. DOI: 10.1016/S2352-3026(17)30014-5.

3. Lee JJ, Pope JE. 2014; A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 16:435. DOI: 10.1186/s13075-014-0435-y. PMID: 25253302. PMCID: PMC4207310.

4. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. 2014; Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 73:1774–80. DOI: 10.1136/annrheumdis-2013-203380. PMID: 23926057.

5. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. 2006; Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 142:1413–8. DOI: 10.1001/archderm.142.11.1413. PMID: 17116831.

6. Vallejo-Yagüe E, Weiler S, Micheroli R, Burden AM. 2020; Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase. Drug Saf. 43:881–91. DOI: 10.1007/s40264-020-00958-9. PMID: 32533433.

7. Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. 2020; Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 79:1400–13. DOI: 10.1136/annrheumdis-2019-216761. PMID: 32759265. PMCID: PMC7569391.

8. Giménez Poderós T, Gallardo Borge S, Vazquez-Ferreiro P. 2020; Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta-analysis. Pharmacotherapy. 40:1248–64. DOI: 10.1002/phar.2472. PMID: 33064892.

9. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. 2021; Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci. 22:2449. DOI: 10.3390/ijms22052449. PMID: 33671049. PMCID: PMC7957632.